Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML)

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/13/2795366/0/en/Shattuck-Labs-Announces-Positive-Initial-Topline-Data-from-Ongoing-Phase-1-A-B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-in-Frontline-Higher-Risk-Myelodysplastic-.html

– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –

Read more at globenewswire.com

Related news for (STTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.